A follow-up to QROT-067, in which I included audio from a pair of doctors testifying at a state house subcommittee the problem of the "big pharma solution" is that it stimulated almost no IgA, which is vital for the solution to actually treat a respiratory illnesses.

The source, an NIH article, "Covid-19 Vaccine Front Runners and their Nanotechnology Design", October 2021:

"... respiratory viruses are ESPECIALLY DIFFICULT to protect against with vaccines."

Ummmmm...
And as example, they say "the respiratory syncytial virus [RSV - the common cold virus] is a prime example in which there are no approved vaccines, despite considerable efforts".

Wait.. now how again? How can we have yearly a battery of respiratory flu "vaccines" but somehow  have never approved one of the common cold?
Anyway...

"One reason for. vaccine FAILURE against respiratory viruses is that the respiratory tract, including the lungs, is an external mucosal surface that is PROTECTED BY THE GENERATION OF SECRETED IGA ANTIBODIES; yet, the antibodies measured to determine whether an experimental subject has responded to a vaccine often focus on IgG, IgM, or total immunoglobulin in the blood."

"Most vaccines are delivered intramuscularly, and mucosal immunity and IgA secretion IS THEREBY MINIMAL. Furthermore, ELICITING IgA PRODUCTION from conventional vaccines is DIFFICULT, and vaccines may LACK the immunogenicity [ the ability of a foreign substance to provoke an immune response] REQUIRED to elicit NECESSARY IgA PROTECTION."
 
Note these quotes don't come from the part of the review that is about what might be speculative or proposed. Rather it comes from the matter-of-fact background section. 

Thanks for listening. I am not on social media much, so please "like" directly on the podcast or specific episode. Also, activate notifications so you can more consistently find out about episodes to which you may want to listen

Note though that I referred in the podcast to this as a study. It is a review.